A New Weapon for Attacking Tumor Blood Vessels  

Oleh:

Semenza, Gregg L.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 19 (May 2008), page 2066.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The approval by the Food and Drug Administration of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF),1 sparked enormous excitement among oncologists. Bevacizumab, the first cancer therapy that acts by blocking angiogenesis, is the result of the successful translation of pioneering work by the late Judah Folkman and his colleagues, who proposed that vascularization is essential for the growth of clinically relevant invasive carcinomas. A recent study by Fischer and colleagues2 indicates that a monoclonal antibody against another angiogenic protein, placental growth factor (PlGF), may also be a useful antiangiogenic therapy for cancer in humans. Tumor cells . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali